Skip to content
Markets News
Stocks1 min read

FDA Accepts Celcuity Application for REVTORPYK in Mutant Breast Cancer

Makkler Newsroom
November 9, 2026 · Based on reporting by GlobeNewswire

The FDA set a June 25, 2027, target date to review Celcuity’s application for patients with PIK3CA-mutant breast cancer.

Key takeaways

  • The FDA accepted Celcuity’s supplemental application for REVTORPYK in PIK3CA-mutant breast cancer.
  • The FDA set a June 25, 2027, review goal date.
  • The application draws on the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 trial.

Celcuity said the FDA accepted its supplemental application for REVTORPYK to treat certain patients with PIK3CA-mutant breast cancer. The FDA set a June 25, 2027, goal date for its decision.

The application covers patients with hormone receptor-positive, HER2-negative locally advanced or metastatic disease whose cancer progressed during or after at least one line of endocrine therapy in the metastatic setting. It is based on data from the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 trial.

The FDA approved REVTORPYK in July 2026, in combination with fulvestrant, with or without palbociclib, for a similar patient group without a detected PIK3CA mutation.

Topics
CELCREVTORPYK
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.